pemetrexed + cisplatin

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Urologic Neoplasms

Conditions

Urologic Neoplasms

Trial Timeline

Aug 1, 2006 → Apr 1, 2008

NCT ID

NCT00374868

About pemetrexed + cisplatin

pemetrexed + cisplatin is a phase 1/2 stage product being developed by Eli Lilly for Urologic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00374868. Target conditions include Urologic Neoplasms.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00040625	Pre-clinical	Completed	—	—	Mesothelioma
NCT01000480	Phase 2	Completed	Oct 1, 2009	Jul 1, 2013	Non Small Cell Lung Cancer
NCT00887549	Phase 2	Completed	Apr 1, 2009	Jun 1, 2011	Non-Small Cell Lung Cancer
NCT00895648	Phase 2	Terminated	Jan 1, 2009	Oct 1, 2012	Mesothelioma
NCT00475657	Phase 2	Terminated	Oct 1, 2007	Apr 1, 2008	Small Cell Lung Cancer
NCT00447421	Phase 1/2	Terminated	Feb 1, 2007	May 1, 2008	Small Cell Lung Cancer
NCT00415168	Phase 2	Completed	Dec 1, 2006	Jul 1, 2009	Gastric Cancer
NCT00386815	Phase 2	Completed	Oct 1, 2006	Feb 1, 2007	Malignant Pleural Mesothelioma
NCT00374868	Phase 1/2	Completed	Aug 1, 2006	Apr 1, 2008	Urologic Neoplasms
NCT00259285	Phase 2	Terminated	Nov 1, 2005	Dec 1, 2007	Non-Small-Cell Lung Cancer
NCT00251550	Phase 1/2	Completed	Oct 1, 2005	Aug 1, 2006	Malignant Pleural Mesotherioma
NCT00191308	Phase 2	Completed	May 1, 2005	Dec 1, 2010	Non-Small Cell Lung Cancer
NCT00320515	Phase 1/2	Completed	Mar 1, 2004	Jul 1, 2008	Neoplasm, Gastric
NCT00190801	Phase 2	Completed	Sep 1, 2003	Sep 1, 2005	Gastrointestinal Neoplasms
NCT00087698	Phase 2	Completed	Sep 1, 2003	Feb 1, 2008	Pleural Neoplasms

Competing Products

16 competing products in Urologic Neoplasms

See all competitors

Product	Company	Stage	Hype Score
Mirabegron + Solifenacin succinate + Placebo	Astellas Pharma	Phase 2	52
Mirabegron + Solifenacin succinate	Astellas Pharma	Phase 3	77
Gemcitabine	Eli Lilly	Phase 2	52
pemetrexed	Eli Lilly	Phase 2	52
ALIMTA + gemcitabine	Eli Lilly	Phase 2	52
BBI503	Sumitomo Pharma	Phase 2	52
Pembrolizumab Injection [Keytruda]	Merck	Phase 2	52
Carboplatin/Paclitaxel + Pembrolizumab	Merck	Phase 2	52
zoledronic acid	Novartis	Phase 2	52
mycophenolate mofetil	Roche	Phase 1	33
Cetuximab + Paclitaxel	Bristol Myers Squibb	Phase 2	51
Nivolumab + Relatlimab	Bristol Myers Squibb	Phase 2	51
CBT101 + Placebo	Brain Biotech	Phase 1	25
OGX-427 600 mg + OGX-427 1000 mg + Placebo + Gemcitabine + Cisplatin + Carboplatin	Achieve Life Sciences	Phase 2	44
S-8184 Paclitaxel Injectable Emulsion + Experimental Arm: TOCOSOL Paclitaxel	Achieve Life Sciences	Phase 2	44
Stem Cell	Brain Biotech	Phase 1	25

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved